

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-5. (Canceled)

6. (Currently Amended) An isolated, enriched, or purified polypeptide, comprising ~~(a)~~ an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:8 and has phosphatase activity;

~~wherein said polypeptide is involved in at least one of integrin signal transduction, the TAK1 signaling pathway, a cellular channel, a cyclin dependent kinase, and the Ras pathway.~~

7.-32. (Canceled)

33. (Currently Amended) An isolated, enriched, or purified polypeptide, comprising an amino acid sequence depicted in SEQ ID NO:8 except that the polypeptide lacks one or more, but not all, of the domains selected from the group consisting of an N terminal domain, ~~a C terminal catalytic domain, a catalytic domain,~~ a C terminal domain, a coiled coil structure region, a spacer region and a C terminal tail;

wherein said polypeptide has phosphatase activity.

34. (Previously Presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 8.

35. (Previously Presented) An isolated polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 8.

36. (Currently Amended) An isolated polypeptide comprising a fragment of SEQ ID NO: 8, wherein said fragment comprises at least 200 contiguous amino acids of SEQ ID NO: 8 and a catalytic domain, and wherein said fragment has phosphatase activity.

37. (Currently Amended) An isolated polypeptide comprising a fragment of SEQ ID NO: 8, wherein said fragment comprises at least 300 contiguous amino acids of SEQ ID NO: 8 and a catalytic domain, and wherein said fragment has phosphatase activity.